Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
4.6 Overcoming translational barriers: In Vivo stability and manufacturing hurdles Despite the immense preclinical promise of nanomedicine in osteosarcoma, several significant translational barriers must be addressed before clinical implementation (59, 68)
Drip of for I.V
Sikiric's group in Croatia) ZERO randomized controlled trials in humans Only one small retrospective human study (not a clinical trial) Animal studies show promise, but
Glutathione deficiency and oxidative stress have been implicated in the pathogenesis of neurological diseases such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis
doi:10.1097/MOG.0b013e3283505a3b
)
